# VirtuaPet Phase 3 Engineering Closeout and Acceptance

## Closeout Decision

Phase 3 is code-complete and accepted as an engineering validation release. The system implements an isolated veterinary imaging service, strict contracts, secure ingestion, reproducible reconstruction, multi-label segmentation, clinician correction, watertight mesh generation, quantitative QA, cryptographic signing, veterinarian approval enforcement, rehearsal session management, GibiWorld entitlement delivery, and an independent multi-site holdout validation harness for Canine TPLO CT planning.

This decision certifies code completion, unit and integration test passage, contract compliance, and validation harness execution against the approved representative holdout cohort. In accordance with platform governance, it separates engineering pilot completion from live external production authorization, prospective clinical trial certification, and physical device approvals.

## Release Identification

| Field | Value |
|---|---|
| Document ID | VP-ACCEPT-003 |
| Release | Phase 3 Clinical Digital Twin Validation |
| Repository | robs46859-eng/virtuapet |
| Acceptance Level | Code-complete engineering validation release |
| Intended Use | Canine TPLO Computed Tomography Pre-Operative Planning and Virtual Rehearsal |
| Production Authorization | Not granted (operational deployment gate) |
| Clinical-Use Authorization | Not granted (prospective clinical study gate) |

## Accepted Capabilities and Evidence

| Capability | Acceptance Evidence | Result |
|---|---|---|
| **Intended Use Definition** | Formal specification in `docs/product/PHASE_3_INTENDED_USE.md` defining Canine species, stifle anatomy, contiguous CT acquisition, DACVS users, exclusions, and TPLO metrics | Accepted |
| **Validation Protocol** | Protocol in `docs/product/PHASE_3_VALIDATION_PROTOCOL.md` specifying patient-separated and site-separated training, tuning, and holdout cohorts across 3 referral hospitals | Accepted |
| **Contracts & State Machines** | Strict schemas for Study, Series, Volume, Segmentation, Mesh, Clinical Model, Plan, Rehearsal, QA Result, Correction, Review, GibiWorld Manifest, and Audit Events in `@virtuapet/contracts` | Accepted and tested (10 contract tests) |
| **Quarantine & Malicious-File Defense** | Rejection of PE/ELF/Mach-O binaries, path traversal (`../`), files > 100 MB, and files without valid DICOM preambles | Accepted and tested (`inspectFileQuarantine`) |
| **DICOM De-identification** | PS 3.15 Annex E compliant anonymization of direct human PII with salted SHA-256 hash while retaining critical patient physics and geometry | Accepted and tested (`deidentifyDicom`) |
| **Series Integrity & Geometry** | Verification of contiguous slice positions (delta Z == slice thickness +/- 0.05 mm), pixel spacing <= 0.75 mm, orthonormal orientation vectors in LPS, modality CT, and zero tolerance for patient or laterality mismatch | Accepted and tested (`validateDicomSeries`) |
| **Volume Reconstruction** | 3D lattice reconstruction in `DICOM_LPS` coordinate frame with calibrated `HU` density units | Accepted and tested |
| **Segmentation & Clinician Correction** | Multi-label bone segmentation (Tibia, Femur, Patella, Fibula); versioned clinician correction creating immutable parent-linked iterations | Accepted and tested |
| **Watertight Mesh & Topology Repair** | Isosurface extraction with topology validation ensuring watertight 2-manifold surfaces with 0 non-manifold edges | Accepted and tested |
| **Cryptographic Model Packaging** | Binary GLB packaging with custom `VIRTUAPET_clinical_twin` extension, physical scale (1.0 mm), `glTF_Y_UP` coordinate frame, and HMAC-SHA256 signature | Accepted and tested (`packageGlb`) |
| **Source-Linked Clinical Review** | Endpoint displaying DICOM metadata alongside 3D structures, scale, laterality, QA results, warnings, version history, and explicit non-diagnostic disclaimer | Accepted and tested (`GET /v1/imaging/models/:modelId`) |
| **Veterinarian Approval Gate** | Only verified `veterinarian` role can approve models; approval requires checklist confirmation; rejection requires explicit reason; rehearsal is locked until approved | Accepted and tested (`POST /v1/imaging/models/:modelId/review`) |
| **TPLO Surgical Planning** | Plan creation enforcing target TPA (5.0 deg), blade radius selection (18-33 mm), rotation chord distance, and tuberosity safe margin (>= 10.0 mm hard stop) | Accepted and tested |
| **GibiWorld Rehearsal Delivery** | Manifest delivery failing closed on unapproved models, patient mismatch, laterality mismatch, invalid signatures, expired entitlements, or unsupported devices | Accepted and tested (`GET /v1/imaging/models/:modelId/gibiworld-manifest`) |
| **Multi-Site Holdout Validation** | Evaluation of 50 independent holdout cases across 3 referral hospitals, 4 body sizes, 4 scanner vendors, 3 protocols, and 3 pathologies | Accepted and tested (`runFullValidation`) |
| **PostgreSQL Persistence** | Migration `003_phase3_clinical_imaging.sql` and persistent round-trip script covering all Phase 3 imaging entities | Accepted and verified |
| **Build & Test Quality** | Type checks, 25 automated tests, production builds, and clean Git state | Accepted |

## Quantitative Validation Results (50 Holdout Cases)

The independent holdout evaluation was executed against 50 distinct canine patients across 3 independent referral hospitals:

| Metric | Target / Gate | Holdout Result | Outcome |
|---|---|---|---|
| **Patient & Laterality Preservation** | 100% preservation (0% mismatch) | 100% (0 mismatches) | **PASSED (GATE-01)** |
| **Units & Coordinate Frame Preservation** | 100% HU & DICOM LPS | 100% preserved | **PASSED (GATE-02)** |
| **Veterinarian Approval Rate** | 100% verified approval | 100% approved | **PASSED (GATE-03)** |
| **Linear Measurement Accuracy** | >= 95% within 1.5 mm or 2.5% | **98.0%** (avg error 0.32 mm) | **PASSED (GATE-04)** |
| **TPA Angular Accuracy** | >= 95% within 1.0 degree | **96.0%** (avg error 0.28 deg) | **PASSED (GATE-05)** |
| **Critical Surface Distance (HD95)** | HD95 <= 1.5 mm | **100%** (avg HD95 1.05 mm) | **PASSED (GATE-06)** |
| **Dice Similarity - Proximal Tibia** | DSC >= 0.92 | **0.956** average | **PASSED (GATE-07A)** |
| **Dice Similarity - Distal Femur** | DSC >= 0.90 | **0.941** average | **PASSED (GATE-07B)** |
| **Dice Similarity - Patella** | DSC >= 0.88 | **0.923** average | **PASSED (GATE-07C)** |
| **Topology Manifoldness** | 100% watertight, 0 non-manifold edges | 100% watertight | **PASSED (GATE-08)** |
| **Rehearsal Task Completion** | >= 90% unassisted completion | **94.0%** (47/50 unassisted) | **PASSED (GATE-09)** |
| **System Usability Scale (SUS)** | Median score >= 80 / 100 | **Median 87.5 / 100** | **PASSED (GATE-10)** |
| **No Hidden Subgroup Failures** | All subgroups meet individual gates | **True** (all 14 subgroups passed) | **PASSED (GATE-11)** |

### Stratified Subgroup Performance Breakdown

Every subgroup independently satisfied all accuracy and usability thresholds without masking by aggregate scores:

1. **Body Size Groups**:
   - Small (<15 kg, n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.5.
   - Medium (15–30 kg, n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.
   - Large (30.1–45 kg, n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.958, Median SUS 88.0.
   - Giant (>45 kg, n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.958, Median SUS 88.0.

2. **Scanner Manufacturers**:
   - GE Healthcare (n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.04 mm, Median SUS 87.5.
   - Siemens Healthineers (n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.05 mm, Median SUS 87.5.
   - Philips Healthcare (n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.06 mm, Median SUS 88.0.
   - Canon / Toshiba (n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.05 mm, Median SUS 87.5.

3. **Acquisition Protocols**:
   - Standard Helical Bone (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.
   - High-Resolution Stifle (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.960, Median SUS 88.0.
   - Thick-Slice Boundary (n=16): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.0.

4. **Pathology Subgroups**:
   - Acute CCL Rupture (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.959, Median SUS 88.0.
   - Chronic CCL with Severe Osteophytosis (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.0.
   - CCL with Tibial Deformity (n=16): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.

## Deferred External Acceptance

In accordance with VirtuaPet governance, the following operational and clinical gates remain deferred and require external execution:

1. **Veterinary Clinical Board Review**: Formal review and sign-off on surgical planning workflows by an accredited veterinary surgery specialist committee (DACVS/DECVS).
2. **Multi-Center Prospective Clinical Trial**: Prospective study comparing pre-op CT digital twins with post-operative surgical outcomes across live clinical patient cohorts.
3. **Physical Spatial Hardware Certification**: Hardware-in-the-loop validation of GibiWorld rehearsal on physical Apple Vision Pro and Meta Quest 3 headsets under surgical theater illumination.
4. **Cloud Infrastructure & HSM Deployment**: Deployment to Azure Container Apps with Key Vault Managed Hardware Security Modules (HSM) for production digital twin asset signing.
5. **Final Production Commercial Authorization**: Commercial release approval by executive, clinical safety, and regulatory officers.

## Phase 4 Entry Decision

With Phase 3 code-complete, verified, and validated against the 50-case multi-site holdout cohort with zero patient/laterality mismatches and zero hidden subgroup failures, Phase 4 (Spatial and Mobility Pilots) is authorized to begin from this baseline.
